BRU · UCB.BR
UCB S.A.
€280.00+€9.50 (+3.51%)
UCB S.A.’s quoted price sits in the upper half of its reported 52-week range, 3.28% below the high.
Loading market information…
BRU · TUB.BR · EUR
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 04:38 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Financière de Tubize S.A.’s quoted price sits in the upper half of its reported 52-week range, 9.14% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Financière de Tubize S.A.’s forward annual dividend is €0.49 per share, paid monthly. The forward yield is 0.21% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Financière de Tubize S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Financière de Tubize SA holds a stake in UCB, a biopharmaceutical company in Belgium. It focuses on the discovery and development of treatments for patients suffering from diseases affecting immune or central nervous system. The company was founded in 1928 and is based in Brussels, Belgium.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:07 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€280.00+€9.50 (+3.51%)
UCB S.A.’s quoted price sits in the upper half of its reported 52-week range, 3.28% below the high.
€28.90+€0.34 (+1.19%)
Lakefront Biotherapeutics’s quoted price sits in the upper half of its reported 52-week range, 5.92% below the high.
€23.40-€0.45 (-1.89%)
Fagron N.V.’s quoted price sits in the upper half of its reported 52-week range, 7.51% below the high.
€16.46+€0.12 (+0.73%)
Ion Beam Applications S.A.’s quoted price sits in the upper half of its reported 52-week range, 7.32% below the high.
$7.95-$0.01 (-0.13%)
AgomAb Therapeutics N.V. American Depositary Shares’s quoted price sits in the lower half of its reported 52-week range, 55.39% below the high.
€3.86+€0.21 (+5.75%)
Hyloris Pharmaceuticals S.A.’s quoted price sits in the lower half of its reported 52-week range, 54.05% below the high.
